Stockscreener 앱 받기
17.64
1.15%
0.20
시간 외 거래:
17.85
0.21
+1.19%
Viatris Inc 주식(VTRS)의 최신 뉴스
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio - TradingView
An offer for all Pacira BioSciences (PCRX) shares is planned but has not yet begun. - Stock Titan
Lumen Technologies, Inc. Common Stock (LUMN) Stock Forecasts - Yahoo! Finance Canada
Pacira BioSciences jumps 44% after Viatris agre... - Pluang
Pacira BioSciences (Nasdaq: PCRX) Makes 52 Week High on Acquisition News - Investorideas.com
Viatris Inc. entered into a definitive agreement to acquire Pacira BioSciences, Inc. for $1.6 billion. - marketscreener.com
Viatris to Acquire Pacira BioSciences for $36.50 Per Share in $1.65 Billion Cash Deal - Minichart
Why Pacira BioSciences Skyrocketed Today - The Motley Fool
Viatris to acquire Pacira BioSciences for $1.65 billion By Investing.com - Investing.com India
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies - Viatris Newsroom
VTRS vs. AVTR: Which Stock Is the Better Value Option? - Zacks Investment Research
Should Value Investors Buy Viatris (VTRS) Stock? - Zacks Investment Research
Viatris (VTRS) is a Top-Ranked Momentum Stock: Should You Buy? - Zacks Investment Research
Lumen Technologies, Inc. Common Stock (LUMN) stock price, news, quote and history - Yahoo Finance UK
Form 4 Viatris Inc For: 3 October By Investing.com - Investing.com Nigeria
Form 4 Viatris Inc For: 3 October By Investing.com - Investing.com South Africa
Form 4 Viatris Inc For: 3 October By Investing.com - Investing.com UK
Is WisdomTree U.S. MidCap Dividend ETF (DON) a Strong ETF Right Now? - Zacks Investment Research
Why Viatris (VTRS) is a Top Value Stock for the Long-Term - Zacks Investment Research
Viatris (NasdaqGS:VTRS) Stock Forecast & Analyst Predictions - Simply Wall Street
Viatris Inc. (VTRS) stock price, news, quote and history - Yahoo Finance UK
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033 - TradingView
Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033 - TradingView
Here's Why Viatris (VTRS) is a Strong Value Stock - Eastern Progress
Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy? - Eastern Progress
Here's Why Viatris (VTRS) is a Strong Momentum Stock - Eastern Progress
Viatris, Long Chau launch lipid disorder management campaign - VnExpress International
Viatris: Strong Cash Generation And Pipeline Progress Keep The Re-Rating Story Alive - Seeking Alpha
VTRS - Finviz
Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy? - Eastern Progress
Leerink Partners Initiates Viatris at Outperform With $20 Price Target - marketscreener.com
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Viatris gets 11% passive stake disclosed by FMR | VTRS SEC FilingForm SCHEDULE 13G/A - Stock Titan
Argus Research Upgrades Viatris(VTRS.US) to Buy Rating, Announces Target Price $20 - Moomoo
Argus Adjusts Price Target on Viatris to $20 From $18, Keeps Buy Rating - marketscreener.com
Argus Adjusts Price Target on Viatris to $20 From $18, Keeps Buy Rating - Moomoo
Viatris Inc. (VTRS) Stock Analysis: Evaluating the Healthcare Giant’s 9.60% Potential Upside for Investors - DirectorsTalk Interviews
Viatris (VTRS) Q2 2026 Earnings Call Transcript - Fortune
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
Viatris Inc. stock rises Monday, outperforms market - MarketWatch
Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and Viatris - Yahoo Finance
Viatris Inc. (VTRS) Stock Analysis: Exploring Its 13% Upside Potential And Dividend Appeal - DirectorsTalk Interviews
Viatris (VTRS) Faces Fresh Generic Earnings Questions, Is The 12% Discount Enough? - Yahoo Finance
Viatris Inc (VTRS) Shares Fall 3.3% -- GF Value Says Still Overv - GuruFocus
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Viatris Inc (VTRS): A Closer Look Behind a 60 GF Score - GuruFocus
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Viatris Inc. (VTRS) Stock Analysis: Exploring a 13.36% Potential Upside Amidst Mixed Financial Signals - DirectorsTalk Interviews
Viatris' China Policy Concerns Overstated, UBS Says - Moomoo
Viatris' China Policy Concerns Overstated, UBS Says - marketscreener.com
3.07%
자본화:
|
볼륨(24시간):